nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—SSTR4—mouth—head and neck cancer	0.0265	0.322	CbGeAlD
Octreotide—MPO—saliva—head and neck cancer	0.0145	0.177	CbGeAlD
Octreotide—SSTR4—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.0114	0.0341	CbGpPWpGaD
Octreotide—SSTR4—head—head and neck cancer	0.00956	0.116	CbGeAlD
Octreotide—SSTR4—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00942	0.0281	CbGpPWpGaD
Octreotide—Gastrointestinal symptom NOS—Hydroxyurea—head and neck cancer	0.00938	0.0161	CcSEcCtD
Octreotide—Peptic ulcer—Vinblastine—head and neck cancer	0.00905	0.0155	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—CEBPA—head and neck cancer	0.00875	0.0261	CbGpPWpGaD
Octreotide—SSTR3—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00867	0.0258	CbGpPWpGaD
Octreotide—SSTR1—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00831	0.0248	CbGpPWpGaD
Octreotide—Neuritis—Vinblastine—head and neck cancer	0.0081	0.0139	CcSEcCtD
Octreotide—SSTR3—head—head and neck cancer	0.00779	0.0949	CbGeAlD
Octreotide—MPO—C-MYB transcription factor network—CCNA1—head and neck cancer	0.00771	0.023	CbGpPWpGaD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00768	0.0229	CbGpPWpGaD
Octreotide—SSTR5—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00737	0.022	CbGpPWpGaD
Octreotide—Numbness—Vinblastine—head and neck cancer	0.0073	0.0125	CcSEcCtD
Octreotide—Local reaction—Fluorouracil—head and neck cancer	0.00717	0.0123	CcSEcCtD
Octreotide—SSTR3—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00714	0.0213	CbGpPWpGaD
Octreotide—Sensory loss—Vinblastine—head and neck cancer	0.00698	0.012	CcSEcCtD
Octreotide—Extravasation—Vinblastine—head and neck cancer	0.00693	0.0119	CcSEcCtD
Octreotide—SSTR1—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00685	0.0204	CbGpPWpGaD
Octreotide—SSTR2—Peptide ligand-binding receptors—KISS1—head and neck cancer	0.00681	0.0203	CbGpPWpGaD
Octreotide—Gastrointestinal symptom NOS—Fluorouracil—head and neck cancer	0.00675	0.0116	CcSEcCtD
Octreotide—Rectal haemorrhage—Vinblastine—head and neck cancer	0.0067	0.0115	CcSEcCtD
Octreotide—Cellulitis—Vinblastine—head and neck cancer	0.00665	0.0114	CcSEcCtD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00632	0.0188	CbGpPWpGaD
Octreotide—Amenorrhoea—Hydroxyurea—head and neck cancer	0.00628	0.0108	CcSEcCtD
Octreotide—SSTR1—head—head and neck cancer	0.00616	0.075	CbGeAlD
Octreotide—Nail disorder—Fluorouracil—head and neck cancer	0.00612	0.0105	CcSEcCtD
Octreotide—SSTR5—Peptide ligand-binding receptors—GRP—head and neck cancer	0.00607	0.0181	CbGpPWpGaD
Octreotide—SSTR4—GPCR ligand binding—KISS1—head and neck cancer	0.00585	0.0174	CbGpPWpGaD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00582	0.0173	CbGpPWpGaD
Octreotide—SSTR2—Peptide ligand-binding receptors—GRP—head and neck cancer	0.0056	0.0167	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00558	0.0166	CbGpPWpGaD
Octreotide—MPO—Vitamin B12 Metabolism—SOD2—head and neck cancer	0.0055	0.0164	CbGpPWpGaD
Octreotide—SSTR2—head—head and neck cancer	0.00524	0.0638	CbGeAlD
Octreotide—Phlebitis—Vinblastine—head and neck cancer	0.0051	0.00876	CcSEcCtD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00495	0.0147	CbGpPWpGaD
Octreotide—Tingling sensation—Fluorouracil—head and neck cancer	0.00494	0.00849	CcSEcCtD
Octreotide—Deafness—Vinblastine—head and neck cancer	0.00491	0.00843	CcSEcCtD
Octreotide—Stinging—Fluorouracil—head and neck cancer	0.0049	0.00842	CcSEcCtD
Octreotide—Haemorrhoids—Docetaxel—head and neck cancer	0.00487	0.00837	CcSEcCtD
Octreotide—SSTR4—GPCR ligand binding—GRP—head and neck cancer	0.00481	0.0143	CbGpPWpGaD
Octreotide—Numbness—Fluorouracil—head and neck cancer	0.00479	0.00823	CcSEcCtD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00479	0.0143	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00459	0.0137	CbGpPWpGaD
Octreotide—Sensory loss—Fluorouracil—head and neck cancer	0.00458	0.00787	CcSEcCtD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00456	0.0136	CbGpPWpGaD
Octreotide—Extravasation—Fluorouracil—head and neck cancer	0.00455	0.00782	CcSEcCtD
Octreotide—MPO—Folate Metabolism—SOD2—head and neck cancer	0.00447	0.0133	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—KISS1—head and neck cancer	0.00443	0.0132	CbGpPWpGaD
Octreotide—Nail disorder—Docetaxel—head and neck cancer	0.00442	0.00759	CcSEcCtD
Octreotide—Cellulitis—Fluorouracil—head and neck cancer	0.00437	0.0075	CcSEcCtD
Octreotide—Herpes simplex—Fluorouracil—head and neck cancer	0.00431	0.0074	CcSEcCtD
Octreotide—MPO—Folate Metabolism—GPX1—head and neck cancer	0.00427	0.0127	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—KISS1—head and neck cancer	0.00425	0.0127	CbGpPWpGaD
Octreotide—Redness—Docetaxel—head and neck cancer	0.00425	0.00729	CcSEcCtD
Octreotide—Intestinal obstruction—Docetaxel—head and neck cancer	0.00421	0.00722	CcSEcCtD
Octreotide—Neuralgia—Docetaxel—head and neck cancer	0.00413	0.00709	CcSEcCtD
Octreotide—Burning sensation—Docetaxel—head and neck cancer	0.00413	0.00709	CcSEcCtD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00407	0.0121	CbGpPWpGaD
Octreotide—Throat sore—Docetaxel—head and neck cancer	0.00398	0.00683	CcSEcCtD
Octreotide—Oropharyngeal discomfort—Docetaxel—head and neck cancer	0.00394	0.00677	CcSEcCtD
Octreotide—Neuritis—Docetaxel—head and neck cancer	0.00384	0.00659	CcSEcCtD
Octreotide—SSTR5—GPCR ligand binding—KISS1—head and neck cancer	0.00377	0.0112	CbGpPWpGaD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00376	0.0112	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—IL2—head and neck cancer	0.0037	0.011	CbGpPWpGaD
Octreotide—Otitis media—Docetaxel—head and neck cancer	0.00368	0.00632	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—GSTM1—head and neck cancer	0.00368	0.011	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—GRP—head and neck cancer	0.00365	0.0109	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—SOD2—head and neck cancer	0.00355	0.0106	CbGpPWpGaD
Octreotide—SSTR1—GPCR ligand binding—GRP—head and neck cancer	0.0035	0.0104	CbGpPWpGaD
Octreotide—SSTR2—GPCR ligand binding—KISS1—head and neck cancer	0.00348	0.0104	CbGpPWpGaD
Octreotide—Pancreatitis—Hydroxyurea—head and neck cancer	0.00339	0.00583	CcSEcCtD
Octreotide—MPO—Selenium Micronutrient Network—GPX1—head and neck cancer	0.00339	0.0101	CbGpPWpGaD
Octreotide—Depression—Vinblastine—head and neck cancer	0.00337	0.0058	CcSEcCtD
Octreotide—MPO—connective tissue—head and neck cancer	0.00337	0.041	CbGeAlD
Octreotide—Thrombophlebitis—Fluorouracil—head and neck cancer	0.00333	0.00572	CcSEcCtD
Octreotide—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00332	0.0057	CcSEcCtD
Octreotide—SSTR4—GPCR downstream signaling—KISS1—head and neck cancer	0.0033	0.00984	CbGpPWpGaD
Octreotide—Extravasation—Docetaxel—head and neck cancer	0.00329	0.00564	CcSEcCtD
Octreotide—Amenorrhoea—Docetaxel—head and neck cancer	0.00326	0.0056	CcSEcCtD
Octreotide—Dysuria—Hydroxyurea—head and neck cancer	0.00324	0.00556	CcSEcCtD
Octreotide—MPO—epithelium—head and neck cancer	0.0032	0.0389	CbGeAlD
Octreotide—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00315	0.00541	CcSEcCtD
Octreotide—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00315	0.00541	CcSEcCtD
Octreotide—Weight increased—Hydroxyurea—head and neck cancer	0.00315	0.00541	CcSEcCtD
Octreotide—MPO—IL23-mediated signaling events—STAT3—head and neck cancer	0.00311	0.00928	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—GRP—head and neck cancer	0.0031	0.00924	CbGpPWpGaD
Octreotide—Drug interaction—Docetaxel—head and neck cancer	0.00309	0.00531	CcSEcCtD
Octreotide—Drowsiness—Hydroxyurea—head and neck cancer	0.00309	0.0053	CcSEcCtD
Octreotide—Amnesia—Fluorouracil—head and neck cancer	0.00307	0.00527	CcSEcCtD
Octreotide—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00303	0.0052	CcSEcCtD
Octreotide—Hypoaesthesia—Vinblastine—head and neck cancer	0.00302	0.00519	CcSEcCtD
Octreotide—Pharyngitis—Vinblastine—head and neck cancer	0.00302	0.00518	CcSEcCtD
Octreotide—Hearing impaired—Docetaxel—head and neck cancer	0.00301	0.00517	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—KISS1—head and neck cancer	0.003	0.00894	CbGpPWpGaD
Octreotide—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00292	0.00501	CcSEcCtD
Octreotide—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00288	0.00495	CcSEcCtD
Octreotide—Osteoarthritis—Fluorouracil—head and neck cancer	0.00288	0.00495	CcSEcCtD
Octreotide—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00287	0.00492	CcSEcCtD
Octreotide—SSTR2—GPCR ligand binding—GRP—head and neck cancer	0.00286	0.00853	CbGpPWpGaD
Octreotide—Injection site reaction—Docetaxel—head and neck cancer	0.00285	0.00489	CcSEcCtD
Octreotide—Influenza like illness—Docetaxel—head and neck cancer	0.00278	0.00478	CcSEcCtD
Octreotide—Irritability—Fluorouracil—head and neck cancer	0.00275	0.00473	CcSEcCtD
Octreotide—Candida infection—Docetaxel—head and neck cancer	0.00274	0.0047	CcSEcCtD
Octreotide—SSTR4—GPCR downstream signaling—GRP—head and neck cancer	0.00272	0.0081	CbGpPWpGaD
Octreotide—Neuropathy—Docetaxel—head and neck cancer	0.00269	0.00462	CcSEcCtD
Octreotide—Alopecia—Vinblastine—head and neck cancer	0.00268	0.00461	CcSEcCtD
Octreotide—Dry skin—Fluorouracil—head and neck cancer	0.00264	0.00454	CcSEcCtD
Octreotide—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00258	0.00443	CcSEcCtD
Octreotide—Muscular weakness—Fluorouracil—head and neck cancer	0.00254	0.00437	CcSEcCtD
Octreotide—SSTR3—GPCR downstream signaling—KISS1—head and neck cancer	0.0025	0.00746	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—GRP—head and neck cancer	0.00247	0.00736	CbGpPWpGaD
Octreotide—MPO—lymphoid tissue—head and neck cancer	0.00246	0.03	CbGeAlD
Octreotide—MPO—IL23-mediated signaling events—PIK3CA—head and neck cancer	0.00246	0.00732	CbGpPWpGaD
Octreotide—Ill-defined disorder—Vinblastine—head and neck cancer	0.00245	0.00422	CcSEcCtD
Octreotide—Alopecia—Hydroxyurea—head and neck cancer	0.00245	0.00421	CcSEcCtD
Octreotide—Anaemia—Vinblastine—head and neck cancer	0.00244	0.0042	CcSEcCtD
Octreotide—Phlebitis—Docetaxel—head and neck cancer	0.00242	0.00415	CcSEcCtD
Octreotide—Erythema—Hydroxyurea—head and neck cancer	0.00241	0.00414	CcSEcCtD
Octreotide—Thrombophlebitis—Docetaxel—head and neck cancer	0.0024	0.00413	CcSEcCtD
Octreotide—SSTR1—GPCR downstream signaling—KISS1—head and neck cancer	0.0024	0.00715	CbGpPWpGaD
Octreotide—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00239	0.00411	CcSEcCtD
Octreotide—Malaise—Vinblastine—head and neck cancer	0.00238	0.0041	CcSEcCtD
Octreotide—Vertigo—Vinblastine—head and neck cancer	0.00238	0.00408	CcSEcCtD
Octreotide—MPO—Folate Metabolism—IL2—head and neck cancer	0.00233	0.00694	CbGpPWpGaD
Octreotide—Deafness—Docetaxel—head and neck cancer	0.00233	0.004	CcSEcCtD
Octreotide—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00232	0.00398	CcSEcCtD
Octreotide—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00229	0.00394	CcSEcCtD
Octreotide—Convulsion—Vinblastine—head and neck cancer	0.00229	0.00394	CcSEcCtD
Octreotide—Hypertension—Vinblastine—head and neck cancer	0.00228	0.00392	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—KISS1—head and neck cancer	0.00227	0.00677	CbGpPWpGaD
Octreotide—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00224	0.00384	CcSEcCtD
Octreotide—Pneumonia—Fluorouracil—head and neck cancer	0.00223	0.00384	CcSEcCtD
Octreotide—Anaemia—Hydroxyurea—head and neck cancer	0.00223	0.00383	CcSEcCtD
Octreotide—Discomfort—Vinblastine—head and neck cancer	0.00222	0.00382	CcSEcCtD
Octreotide—Hot flush—Docetaxel—head and neck cancer	0.00222	0.00382	CcSEcCtD
Octreotide—Menopausal symptoms—Docetaxel—head and neck cancer	0.00221	0.00379	CcSEcCtD
Octreotide—Visual disturbance—Docetaxel—head and neck cancer	0.0022	0.00377	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—BCL2—head and neck cancer	0.00218	0.0065	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—KISS1—head and neck cancer	0.00218	0.00649	CbGpPWpGaD
Octreotide—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00218	0.00374	CcSEcCtD
Octreotide—Malaise—Hydroxyurea—head and neck cancer	0.00218	0.00374	CcSEcCtD
Octreotide—Urinary tract infection—Fluorouracil—head and neck cancer	0.00216	0.00371	CcSEcCtD
Octreotide—Conjunctivitis—Fluorouracil—head and neck cancer	0.00216	0.00371	CcSEcCtD
Octreotide—SSTR5—GPCR downstream signaling—KISS1—head and neck cancer	0.00213	0.00634	CbGpPWpGaD
Octreotide—Thrombocytopenia—Vinblastine—head and neck cancer	0.00211	0.00363	CcSEcCtD
Octreotide—Epistaxis—Fluorouracil—head and neck cancer	0.0021	0.0036	CcSEcCtD
Octreotide—Convulsion—Hydroxyurea—head and neck cancer	0.00209	0.00359	CcSEcCtD
Octreotide—Sinusitis—Fluorouracil—head and neck cancer	0.00208	0.00358	CcSEcCtD
Octreotide—Pain in extremity—Docetaxel—head and neck cancer	0.00208	0.00357	CcSEcCtD
Octreotide—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00208	0.00357	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—PTGS2—head and neck cancer	0.00207	0.00617	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—GRP—head and neck cancer	0.00206	0.00614	CbGpPWpGaD
Octreotide—Anorexia—Vinblastine—head and neck cancer	0.00206	0.00353	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00204	0.0035	CcSEcCtD
Octreotide—Discomfort—Hydroxyurea—head and neck cancer	0.00203	0.00348	CcSEcCtD
Octreotide—Rhinitis—Fluorouracil—head and neck cancer	0.002	0.00343	CcSEcCtD
Octreotide—MPO—Selenium Micronutrient Network—PTGS2—head and neck cancer	0.002	0.00595	CbGpPWpGaD
Octreotide—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00198	0.00341	CcSEcCtD
Octreotide—MPO—head—head and neck cancer	0.00198	0.0241	CbGeAlD
Octreotide—Pharyngitis—Fluorouracil—head and neck cancer	0.00198	0.0034	CcSEcCtD
Octreotide—SSTR1—GPCR downstream signaling—GRP—head and neck cancer	0.00198	0.00589	CbGpPWpGaD
Octreotide—Oedema—Hydroxyurea—head and neck cancer	0.00197	0.00338	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—KISS1—head and neck cancer	0.00196	0.00585	CbGpPWpGaD
Octreotide—Infection—Hydroxyurea—head and neck cancer	0.00196	0.00336	CcSEcCtD
Octreotide—Paraesthesia—Vinblastine—head and neck cancer	0.00194	0.00333	CcSEcCtD
Octreotide—Dehydration—Docetaxel—head and neck cancer	0.00193	0.00332	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—KISS1—head and neck cancer	0.00193	0.00576	CbGpPWpGaD
Octreotide—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00193	0.00332	CcSEcCtD
Octreotide—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00193	0.00331	CcSEcCtD
Octreotide—Skin disorder—Hydroxyurea—head and neck cancer	0.00191	0.00328	CcSEcCtD
Octreotide—Dry skin—Docetaxel—head and neck cancer	0.00191	0.00328	CcSEcCtD
Octreotide—Abdominal pain upper—Docetaxel—head and neck cancer	0.0019	0.00326	CcSEcCtD
Octreotide—Anorexia—Hydroxyurea—head and neck cancer	0.00188	0.00322	CcSEcCtD
Octreotide—Decreased appetite—Vinblastine—head and neck cancer	0.00188	0.00322	CcSEcCtD
Octreotide—Cramp muscle—Docetaxel—head and neck cancer	0.00187	0.00322	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—CCND1—head and neck cancer	0.00187	0.00558	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—GRP—head and neck cancer	0.00187	0.00558	CbGpPWpGaD
Octreotide—Nasopharyngitis—Docetaxel—head and neck cancer	0.00186	0.0032	CcSEcCtD
Octreotide—Pain—Vinblastine—head and neck cancer	0.00185	0.00317	CcSEcCtD
Octreotide—Constipation—Vinblastine—head and neck cancer	0.00185	0.00317	CcSEcCtD
Octreotide—SSTR1—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.00182	0.00541	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—GRP—head and neck cancer	0.00179	0.00535	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—KISS1—head and neck cancer	0.00178	0.00531	CbGpPWpGaD
Octreotide—Arrhythmia—Fluorouracil—head and neck cancer	0.00178	0.00306	CcSEcCtD
Octreotide—Feeling abnormal—Vinblastine—head and neck cancer	0.00178	0.00306	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—KISS1—head and neck cancer	0.00177	0.00528	CbGpPWpGaD
Octreotide—Bronchospasm—Docetaxel—head and neck cancer	0.00177	0.00304	CcSEcCtD
Octreotide—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00177	0.00303	CcSEcCtD
Octreotide—Alopecia—Fluorouracil—head and neck cancer	0.00176	0.00303	CcSEcCtD
Octreotide—Dyspnoea—Hydroxyurea—head and neck cancer	0.00175	0.00301	CcSEcCtD
Octreotide—SSTR5—GPCR downstream signaling—GRP—head and neck cancer	0.00175	0.00522	CbGpPWpGaD
Octreotide—Somnolence—Hydroxyurea—head and neck cancer	0.00175	0.00301	CcSEcCtD
Octreotide—Erythema—Fluorouracil—head and neck cancer	0.00174	0.00298	CcSEcCtD
Octreotide—Dyspepsia—Hydroxyurea—head and neck cancer	0.00173	0.00298	CcSEcCtD
Octreotide—Decreased appetite—Hydroxyurea—head and neck cancer	0.00171	0.00294	CcSEcCtD
Octreotide—Abdominal pain—Vinblastine—head and neck cancer	0.00171	0.00293	CcSEcCtD
Octreotide—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.0017	0.00292	CcSEcCtD
Octreotide—Fatigue—Hydroxyurea—head and neck cancer	0.0017	0.00292	CcSEcCtD
Octreotide—Pain—Hydroxyurea—head and neck cancer	0.00168	0.00289	CcSEcCtD
Octreotide—Constipation—Hydroxyurea—head and neck cancer	0.00168	0.00289	CcSEcCtD
Octreotide—Weight increased—Docetaxel—head and neck cancer	0.00164	0.00281	CcSEcCtD
Octreotide—Vision blurred—Fluorouracil—head and neck cancer	0.00164	0.00281	CcSEcCtD
Octreotide—Weight decreased—Docetaxel—head and neck cancer	0.00163	0.00279	CcSEcCtD
Octreotide—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00162	0.00279	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—GRP—head and neck cancer	0.00162	0.00482	CbGpPWpGaD
Octreotide—Pneumonia—Docetaxel—head and neck cancer	0.00161	0.00277	CcSEcCtD
Octreotide—Anaemia—Fluorouracil—head and neck cancer	0.0016	0.00276	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—GRP—head and neck cancer	0.00159	0.00474	CbGpPWpGaD
Octreotide—Hypersensitivity—Vinblastine—head and neck cancer	0.00159	0.00273	CcSEcCtD
Octreotide—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00157	0.0027	CcSEcCtD
Octreotide—Jaundice—Docetaxel—head and neck cancer	0.00156	0.00268	CcSEcCtD
Octreotide—Conjunctivitis—Docetaxel—head and neck cancer	0.00156	0.00268	CcSEcCtD
Octreotide—Body temperature increased—Hydroxyurea—head and neck cancer	0.00156	0.00267	CcSEcCtD
Octreotide—Asthenia—Vinblastine—head and neck cancer	0.00155	0.00266	CcSEcCtD
Octreotide—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00152	0.0026	CcSEcCtD
Octreotide—Epistaxis—Docetaxel—head and neck cancer	0.00151	0.0026	CcSEcCtD
Octreotide—Convulsion—Fluorouracil—head and neck cancer	0.0015	0.00258	CcSEcCtD
Octreotide—MPO—Folate Metabolism—TP53—head and neck cancer	0.0015	0.00446	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.00149	0.00443	CbGpPWpGaD
Octreotide—Chest pain—Fluorouracil—head and neck cancer	0.00148	0.00254	CcSEcCtD
Octreotide—Myalgia—Fluorouracil—head and neck cancer	0.00148	0.00254	CcSEcCtD
Octreotide—Diarrhoea—Vinblastine—head and neck cancer	0.00148	0.00254	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—GRP—head and neck cancer	0.00147	0.00438	CbGpPWpGaD
Octreotide—Discomfort—Fluorouracil—head and neck cancer	0.00146	0.00251	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—GRP—head and neck cancer	0.00146	0.00435	CbGpPWpGaD
Octreotide—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00145	0.00249	CcSEcCtD
Octreotide—Rhinitis—Docetaxel—head and neck cancer	0.00144	0.00248	CcSEcCtD
Octreotide—Hepatitis—Docetaxel—head and neck cancer	0.00144	0.00247	CcSEcCtD
Octreotide—Hypoaesthesia—Docetaxel—head and neck cancer	0.00143	0.00246	CcSEcCtD
Octreotide—Pharyngitis—Docetaxel—head and neck cancer	0.00143	0.00245	CcSEcCtD
Octreotide—Dizziness—Vinblastine—head and neck cancer	0.00143	0.00245	CcSEcCtD
Octreotide—Oedema peripheral—Docetaxel—head and neck cancer	0.00142	0.00244	CcSEcCtD
Octreotide—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00142	0.00243	CcSEcCtD
Octreotide—Oedema—Fluorouracil—head and neck cancer	0.00142	0.00243	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—STAT6—head and neck cancer	0.00142	0.00422	CbGpPWpGaD
Octreotide—Asthenia—Hydroxyurea—head and neck cancer	0.00141	0.00243	CcSEcCtD
Octreotide—Infection—Fluorouracil—head and neck cancer	0.00141	0.00242	CcSEcCtD
Octreotide—Nervous system disorder—Fluorouracil—head and neck cancer	0.00139	0.00239	CcSEcCtD
Octreotide—MPO—lymph node—head and neck cancer	0.00139	0.0169	CbGeAlD
Octreotide—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00139	0.00238	CcSEcCtD
Octreotide—Visual impairment—Docetaxel—head and neck cancer	0.00139	0.00238	CcSEcCtD
Octreotide—Tachycardia—Fluorouracil—head and neck cancer	0.00138	0.00238	CcSEcCtD
Octreotide—Vomiting—Vinblastine—head and neck cancer	0.00137	0.00236	CcSEcCtD
Octreotide—Headache—Vinblastine—head and neck cancer	0.00135	0.00232	CcSEcCtD
Octreotide—Anorexia—Fluorouracil—head and neck cancer	0.00135	0.00232	CcSEcCtD
Octreotide—Diarrhoea—Hydroxyurea—head and neck cancer	0.00135	0.00231	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—KISS1—head and neck cancer	0.00134	0.004	CbGpPWpGaD
Octreotide—Flushing—Docetaxel—head and neck cancer	0.00134	0.00229	CcSEcCtD
Octreotide—Cardiac disorder—Docetaxel—head and neck cancer	0.00134	0.00229	CcSEcCtD
Octreotide—Dizziness—Hydroxyurea—head and neck cancer	0.0013	0.00224	CcSEcCtD
Octreotide—Immune system disorder—Docetaxel—head and neck cancer	0.0013	0.00223	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00129	0.00222	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—KISS1—head and neck cancer	0.00129	0.00384	CbGpPWpGaD
Octreotide—Arrhythmia—Docetaxel—head and neck cancer	0.00129	0.00221	CcSEcCtD
Octreotide—Nausea—Vinblastine—head and neck cancer	0.00128	0.0022	CcSEcCtD
Octreotide—Insomnia—Fluorouracil—head and neck cancer	0.00128	0.0022	CcSEcCtD
Octreotide—Paraesthesia—Fluorouracil—head and neck cancer	0.00127	0.00219	CcSEcCtD
Octreotide—Alopecia—Docetaxel—head and neck cancer	0.00127	0.00218	CcSEcCtD
Octreotide—Dyspnoea—Fluorouracil—head and neck cancer	0.00126	0.00217	CcSEcCtD
Octreotide—Mental disorder—Docetaxel—head and neck cancer	0.00126	0.00217	CcSEcCtD
Octreotide—Somnolence—Fluorouracil—head and neck cancer	0.00126	0.00216	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—YAP1—head and neck cancer	0.00125	0.00374	CbGpPWpGaD
Octreotide—Malnutrition—Docetaxel—head and neck cancer	0.00125	0.00215	CcSEcCtD
Octreotide—Erythema—Docetaxel—head and neck cancer	0.00125	0.00215	CcSEcCtD
Octreotide—Vomiting—Hydroxyurea—head and neck cancer	0.00125	0.00215	CcSEcCtD
Octreotide—Dyspepsia—Fluorouracil—head and neck cancer	0.00125	0.00214	CcSEcCtD
Octreotide—Rash—Hydroxyurea—head and neck cancer	0.00124	0.00213	CcSEcCtD
Octreotide—Dermatitis—Hydroxyurea—head and neck cancer	0.00124	0.00213	CcSEcCtD
Octreotide—Headache—Hydroxyurea—head and neck cancer	0.00123	0.00212	CcSEcCtD
Octreotide—Decreased appetite—Fluorouracil—head and neck cancer	0.00123	0.00212	CcSEcCtD
Octreotide—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00122	0.0021	CcSEcCtD
Octreotide—Back pain—Docetaxel—head and neck cancer	0.00121	0.00208	CcSEcCtD
Octreotide—Pain—Fluorouracil—head and neck cancer	0.00121	0.00208	CcSEcCtD
Octreotide—Muscle spasms—Docetaxel—head and neck cancer	0.0012	0.00207	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—HRAS—head and neck cancer	0.00118	0.00351	CbGpPWpGaD
Octreotide—Nausea—Hydroxyurea—head and neck cancer	0.00117	0.00201	CcSEcCtD
Octreotide—Feeling abnormal—Fluorouracil—head and neck cancer	0.00117	0.00201	CcSEcCtD
Octreotide—Anaemia—Docetaxel—head and neck cancer	0.00116	0.00199	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—KISS1—head and neck cancer	0.00114	0.0034	CbGpPWpGaD
Octreotide—Urticaria—Fluorouracil—head and neck cancer	0.00113	0.00193	CcSEcCtD
Octreotide—Syncope—Docetaxel—head and neck cancer	0.00112	0.00193	CcSEcCtD
Octreotide—Body temperature increased—Fluorouracil—head and neck cancer	0.00112	0.00192	CcSEcCtD
Octreotide—Palpitations—Docetaxel—head and neck cancer	0.00111	0.0019	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—GRP—head and neck cancer	0.00111	0.00329	CbGpPWpGaD
Octreotide—Loss of consciousness—Docetaxel—head and neck cancer	0.0011	0.00189	CcSEcCtD
Octreotide—Cough—Docetaxel—head and neck cancer	0.00109	0.00188	CcSEcCtD
Octreotide—Convulsion—Docetaxel—head and neck cancer	0.00109	0.00186	CcSEcCtD
Octreotide—Hypertension—Docetaxel—head and neck cancer	0.00108	0.00186	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—STAT6—head and neck cancer	0.00107	0.0032	CbGpPWpGaD
Octreotide—Arthralgia—Docetaxel—head and neck cancer	0.00107	0.00183	CcSEcCtD
Octreotide—Chest pain—Docetaxel—head and neck cancer	0.00107	0.00183	CcSEcCtD
Octreotide—Myalgia—Docetaxel—head and neck cancer	0.00107	0.00183	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—GRP—head and neck cancer	0.00106	0.00316	CbGpPWpGaD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00106	0.00182	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—KISS1—head and neck cancer	0.00105	0.00314	CbGpPWpGaD
Octreotide—Hypersensitivity—Fluorouracil—head and neck cancer	0.00104	0.00179	CcSEcCtD
Octreotide—Dry mouth—Docetaxel—head and neck cancer	0.00104	0.00179	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—STAT6—head and neck cancer	0.00103	0.00307	CbGpPWpGaD
Octreotide—Oedema—Docetaxel—head and neck cancer	0.00102	0.00176	CcSEcCtD
Octreotide—Anaphylactic shock—Docetaxel—head and neck cancer	0.00102	0.00176	CcSEcCtD
Octreotide—Infection—Docetaxel—head and neck cancer	0.00102	0.00175	CcSEcCtD
Octreotide—Shock—Docetaxel—head and neck cancer	0.00101	0.00173	CcSEcCtD
Octreotide—Nervous system disorder—Docetaxel—head and neck cancer	0.001	0.00172	CcSEcCtD
Octreotide—Pruritus—Fluorouracil—head and neck cancer	0.001	0.00172	CcSEcCtD
Octreotide—Thrombocytopenia—Docetaxel—head and neck cancer	0.001	0.00172	CcSEcCtD
Octreotide—Tachycardia—Docetaxel—head and neck cancer	0.000998	0.00171	CcSEcCtD
Octreotide—Skin disorder—Docetaxel—head and neck cancer	0.000993	0.00171	CcSEcCtD
Octreotide—Anorexia—Docetaxel—head and neck cancer	0.000975	0.00167	CcSEcCtD
Octreotide—Diarrhoea—Fluorouracil—head and neck cancer	0.000969	0.00167	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—YAP1—head and neck cancer	0.00095	0.00283	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—GRP—head and neck cancer	0.00094	0.0028	CbGpPWpGaD
Octreotide—Dizziness—Fluorouracil—head and neck cancer	0.000937	0.00161	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000932	0.0016	CcSEcCtD
Octreotide—Insomnia—Docetaxel—head and neck cancer	0.000925	0.00159	CcSEcCtD
Octreotide—Paraesthesia—Docetaxel—head and neck cancer	0.000918	0.00158	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—STAT6—head and neck cancer	0.000913	0.00272	CbGpPWpGaD
Octreotide—Dyspnoea—Docetaxel—head and neck cancer	0.000912	0.00157	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—YAP1—head and neck cancer	0.000911	0.00271	CbGpPWpGaD
Octreotide—Somnolence—Docetaxel—head and neck cancer	0.000909	0.00156	CcSEcCtD
Octreotide—Vomiting—Fluorouracil—head and neck cancer	0.000901	0.00155	CcSEcCtD
Octreotide—Dyspepsia—Docetaxel—head and neck cancer	0.0009	0.00155	CcSEcCtD
Octreotide—Rash—Fluorouracil—head and neck cancer	0.000893	0.00153	CcSEcCtD
Octreotide—Dermatitis—Fluorouracil—head and neck cancer	0.000893	0.00153	CcSEcCtD
Octreotide—Decreased appetite—Docetaxel—head and neck cancer	0.000889	0.00153	CcSEcCtD
Octreotide—Headache—Fluorouracil—head and neck cancer	0.000888	0.00152	CcSEcCtD
Octreotide—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000883	0.00152	CcSEcCtD
Octreotide—Fatigue—Docetaxel—head and neck cancer	0.000882	0.00151	CcSEcCtD
Octreotide—Pain—Docetaxel—head and neck cancer	0.000875	0.0015	CcSEcCtD
Octreotide—Constipation—Docetaxel—head and neck cancer	0.000875	0.0015	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—GRP—head and neck cancer	0.000868	0.00259	CbGpPWpGaD
Octreotide—Feeling abnormal—Docetaxel—head and neck cancer	0.000843	0.00145	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—STAT6—head and neck cancer	0.000842	0.00251	CbGpPWpGaD
Octreotide—Nausea—Fluorouracil—head and neck cancer	0.000842	0.00145	CcSEcCtD
Octreotide—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000836	0.00144	CcSEcCtD
Octreotide—Abdominal pain—Docetaxel—head and neck cancer	0.000808	0.00139	CcSEcCtD
Octreotide—Body temperature increased—Docetaxel—head and neck cancer	0.000808	0.00139	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—YAP1—head and neck cancer	0.000808	0.00241	CbGpPWpGaD
Octreotide—Hypersensitivity—Docetaxel—head and neck cancer	0.000753	0.00129	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—YAP1—head and neck cancer	0.000746	0.00222	CbGpPWpGaD
Octreotide—Asthenia—Docetaxel—head and neck cancer	0.000734	0.00126	CcSEcCtD
Octreotide—SSTR4—GPCR downstream signaling—IL2—head and neck cancer	0.000725	0.00216	CbGpPWpGaD
Octreotide—Pruritus—Docetaxel—head and neck cancer	0.000724	0.00124	CcSEcCtD
Octreotide—Diarrhoea—Docetaxel—head and neck cancer	0.0007	0.0012	CcSEcCtD
Octreotide—Dizziness—Docetaxel—head and neck cancer	0.000676	0.00116	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—IL2—head and neck cancer	0.000658	0.00196	CbGpPWpGaD
Octreotide—Vomiting—Docetaxel—head and neck cancer	0.00065	0.00112	CcSEcCtD
Octreotide—Rash—Docetaxel—head and neck cancer	0.000645	0.00111	CcSEcCtD
Octreotide—Dermatitis—Docetaxel—head and neck cancer	0.000644	0.00111	CcSEcCtD
Octreotide—Headache—Docetaxel—head and neck cancer	0.000641	0.0011	CcSEcCtD
Octreotide—Nausea—Docetaxel—head and neck cancer	0.000607	0.00104	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—NOTCH1—head and neck cancer	0.000565	0.00168	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—IL2—head and neck cancer	0.000549	0.00164	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—MAPK3—head and neck cancer	0.000529	0.00158	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—IL2—head and neck cancer	0.000527	0.00157	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—MAPK1—head and neck cancer	0.000504	0.0015	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—EGFR—head and neck cancer	0.000503	0.0015	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—IL2—head and neck cancer	0.000499	0.00149	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000481	0.00143	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—IL2—head and neck cancer	0.000478	0.00142	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—IL2—head and neck cancer	0.000467	0.00139	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—PIK3CA—head and neck cancer	0.000437	0.0013	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—IL2—head and neck cancer	0.000431	0.00128	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NOTCH1—head and neck cancer	0.000428	0.00128	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—IL2—head and neck cancer	0.000424	0.00126	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NOTCH1—head and neck cancer	0.000411	0.00122	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—HRAS—head and neck cancer	0.000404	0.0012	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—MAPK3—head and neck cancer	0.000401	0.00119	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—AKT1—head and neck cancer	0.000393	0.00117	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—IL2—head and neck cancer	0.000391	0.00117	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—IL2—head and neck cancer	0.000389	0.00116	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—MAPK3—head and neck cancer	0.000385	0.00115	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—MAPK1—head and neck cancer	0.000382	0.00114	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—EGFR—head and neck cancer	0.000382	0.00114	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CCND1—head and neck cancer	0.000379	0.00113	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PTEN—head and neck cancer	0.000366	0.00109	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—MAPK1—head and neck cancer	0.000366	0.00109	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—EGFR—head and neck cancer	0.000366	0.00109	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000365	0.00109	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NOTCH1—head and neck cancer	0.000364	0.00108	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—AKT1—head and neck cancer	0.000357	0.00106	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—PIK3CA—head and neck cancer	0.00035	0.00104	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—MAPK3—head and neck cancer	0.000341	0.00102	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NOTCH1—head and neck cancer	0.000336	0.001	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—PIK3CA—head and neck cancer	0.000331	0.000987	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—VEGFA—head and neck cancer	0.00033	0.000985	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—STAT3—head and neck cancer	0.000327	0.000975	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—MAPK1—head and neck cancer	0.000324	0.000967	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—EGFR—head and neck cancer	0.000324	0.000967	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—PIK3CA—head and neck cancer	0.000317	0.000946	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—MAPK3—head and neck cancer	0.000315	0.000938	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MAPK3—head and neck cancer	0.000313	0.000931	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—PIK3CA—head and neck cancer	0.00031	0.000924	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—HRAS—head and neck cancer	0.000306	0.000913	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—MAPK1—head and neck cancer	0.000299	0.000892	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—EGFR—head and neck cancer	0.000299	0.000892	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—AKT1—head and neck cancer	0.000298	0.000888	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MAPK1—head and neck cancer	0.000297	0.000886	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EGFR—head and neck cancer	0.000297	0.000886	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IL2—head and neck cancer	0.000295	0.000878	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—HRAS—head and neck cancer	0.000294	0.000875	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CCND1—head and neck cancer	0.000287	0.000856	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000286	0.000853	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—AKT1—head and neck cancer	0.000286	0.000851	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IL2—head and neck cancer	0.000283	0.000842	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—PIK3CA—head and neck cancer	0.000282	0.000839	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PTEN—head and neck cancer	0.000277	0.000826	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CCND1—head and neck cancer	0.000275	0.000821	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—AKT1—head and neck cancer	0.000271	0.000806	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PTEN—head and neck cancer	0.000266	0.000792	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—HRAS—head and neck cancer	0.00026	0.000776	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—PIK3CA—head and neck cancer	0.00026	0.000774	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—AKT1—head and neck cancer	0.000259	0.000773	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PIK3CA—head and neck cancer	0.000258	0.000769	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—AKT1—head and neck cancer	0.000253	0.000755	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IL2—head and neck cancer	0.000251	0.000747	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—VEGFA—head and neck cancer	0.00025	0.000746	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TP53—head and neck cancer	0.00025	0.000744	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—STAT3—head and neck cancer	0.000248	0.000739	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CCND1—head and neck cancer	0.000244	0.000728	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—HRAS—head and neck cancer	0.00024	0.000716	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—VEGFA—head and neck cancer	0.00024	0.000715	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—HRAS—head and neck cancer	0.000239	0.000711	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—STAT3—head and neck cancer	0.000238	0.000708	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MAPK3—head and neck cancer	0.000237	0.000706	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PTEN—head and neck cancer	0.000236	0.000702	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—AKT1—head and neck cancer	0.000234	0.000696	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IL2—head and neck cancer	0.000231	0.000689	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—AKT1—head and neck cancer	0.00023	0.000685	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MAPK3—head and neck cancer	0.000227	0.000677	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CCND1—head and neck cancer	0.000225	0.000672	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MAPK1—head and neck cancer	0.000225	0.000672	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EGFR—head and neck cancer	0.000225	0.000671	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PTEN—head and neck cancer	0.000218	0.000648	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MAPK1—head and neck cancer	0.000216	0.000644	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EGFR—head and neck cancer	0.000216	0.000644	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—VEGFA—head and neck cancer	0.000213	0.000634	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—AKT1—head and neck cancer	0.000212	0.000632	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—STAT3—head and neck cancer	0.000211	0.000628	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—AKT1—head and neck cancer	0.000211	0.000628	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MAPK3—head and neck cancer	0.000201	0.0006	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—VEGFA—head and neck cancer	0.000197	0.000586	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PIK3CA—head and neck cancer	0.000196	0.000583	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—STAT3—head and neck cancer	0.000195	0.00058	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MAPK1—head and neck cancer	0.000192	0.000571	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EGFR—head and neck cancer	0.000192	0.000571	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TP53—head and neck cancer	0.000189	0.000564	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PIK3CA—head and neck cancer	0.000188	0.000559	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MAPK3—head and neck cancer	0.000186	0.000554	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TP53—head and neck cancer	0.000181	0.000541	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—HRAS—head and neck cancer	0.000181	0.000539	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MAPK1—head and neck cancer	0.000177	0.000527	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EGFR—head and neck cancer	0.000177	0.000527	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—HRAS—head and neck cancer	0.000174	0.000517	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PIK3CA—head and neck cancer	0.000166	0.000496	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TP53—head and neck cancer	0.000161	0.000479	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—AKT1—head and neck cancer	0.00016	0.000476	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—HRAS—head and neck cancer	0.000154	0.000458	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CA—head and neck cancer	0.000153	0.000457	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—AKT1—head and neck cancer	0.000153	0.000456	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TP53—head and neck cancer	0.000148	0.000442	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—HRAS—head and neck cancer	0.000142	0.000423	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—AKT1—head and neck cancer	0.000136	0.000405	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—AKT1—head and neck cancer	0.000125	0.000374	CbGpPWpGaD
Octreotide—Desmopressin—PTGS2—head and neck cancer	5.39e-05	1	CrCbGaD
